you very us. for thank XXXX and for Good a year AJ. everyone, transformative afternoon, joining Thank much, was Vanda. you
We the continue to long-term company drive success. position and strong growth for
in in efforts our and build employees, ability of As XXXX, in all benefit we we serve. confident our of the to innovate our our for that broader we’re communities our to move great stakeholders, the shareholders, strides on our patients,
highlight Before go in want I of our our moment year. accomplishments a some last I to take into updates, to the key
the HETLIOZ encouraged year-over-year experienced sighted speaks into now years Non-XX blind see treatment. the patients growth product to continued our the products, by to Fanapt. launch, in to as with particular, Looking ability our I’m both talent and sales value we and for team six of sales as dedication commercial for see and first the well In our growth achieve double-digit HETLIOZ, volumes
X, relating Patent pleased we’re the a with ensures November protection petition will Fanapt, This certiorari for filed by remain was of Fanapt. Supreme deny the to Court through of XXXX. a WestWard for For the writ the subsidiary U.S. that Hikma of Patent our ‘XXX decision Pharmaceuticals, ‘XXX to
the out consumer XXXX. the for progress have around Additionally, pace to made first which to roll our launch in Fanapt, we is of half campaign on direct excellent of marketing
XX really late for expected months that to development, critical the and propel our Vanda over milestones an time pipeline are robust clinical Turning several to with of months. a is and our innovation indications next product ongoing stage efforts number to it XX exciting
to study with reported like tradipitant results an a would the receptor start minutes few in atopic update EPIONE programs. ongoing our ago I We of and of tradipitant, pruritus neurokinin-X on said, antagonist, the our provide That of dermatitis. in treatment
its the did reduction overall The of endpoint not primary across population. pruritus meet study in EPIONE study
of the is robust was the dermatitis However, population. of atopic AD study population the AD well to Mild over total tradipitant, and tolerated. continue demonstrate antipruritic the EPIONE The States. in the United effect in represents XX% mild tradipitant study safe
addresses safe the AD. a are a Although severity of used first we’re of of much coupled may the suffer severe meet and therapy but primary this treatment study for majority only its The therapies the potent full patients pruritus. systemic its did of lesion significant immunosuppressive AD day reduction and large moderate to onset by AD in need that effects, a tradipitant for to not patients. of EPIONE significant still treating of portion with demonstrated severe experience provide intractable profile a of AD immediate for mild typically profile from their pruritus current needed highly endpoint, disappointed that unmet AD Due efficacy potentially in
either baseline severity Patients assessed number for Phase of severity intervals. a post was pruritus randomized of mild weeks. eight a at population the IGA. placebo as controlled of regular or and to treatment performed scale them, severe XX% with presentation and to severe assessment scales XX% one-to-one placebo of with EPIONE or randomization a from randomized treat receive patients at range intent and study a were tradipitant global moderate in period patients symptomatic by with were XXX Patients investigator’s XX% with determined to disease X of the disease
Worst improvement not Itch Numeric between tradipitant a was of eight, tradipitant over AD day The EPIONE of treatment symptoms significant period. disease milligrams placebo, that study signs and evaluation by the groups of meaningful At Rating tradipitant the the week as improvement the of the that significant. measured was in examined and hypothesis WI-NRS, demonstrated while placebo patients XX than greater pruritus but scale, the and dose statistically improvement margin at offers difference twice
a one P value accounted suggests was different baseline a experienced different with with This baseline interaction X.XXXX. study and was participants of observed disease pre-specified baseline significantly trial significant through value IGA, significant and that interaction, and the of WI-NRS with A that P treatment When disease in were seen severity treatment that significant at population with improvement full a outcomes. endpoint severity, the severity X.XXXX. and of for in week treatment was disease the eight between tradipitant four larger
Table periods and release were effects our treatment the eight throughout on Similar that of summarized the four, press you one seen six, can comprising weeks data visits all two, at in these are see website. post-randomization
the scores two of severity, a severity Given largest experienced the improvement between one with treatment, and subgroup over with XX% that showed population the observed IGA and of significant disease patients baseline analysis mild interaction placebo. disease
four by this, patients the or more a again was where tradipitant that one significant XX.X% be improved tradipitant compared as are of seen patients difference P meaningful AD mild significant. responding in Table reviewed visit. points XX.X% in clinically of responder of press every categorical again patients showed significantly Specifically, X.XXXX the at had WI-NRS placebo of a as and Table highly that release to placebo response one value with The the analysis over can group, and associated one. WI-NRS in figure And
of effect confirmed daily These significant with results antipruritic entries. AD. suggest patient a in And tradipitant diary and large mild were
immediate response severe Similar after dosing, day the suggesting in was the effect. and of sleep patients, the – AD nighttime immediately observed that of tradipitant showed seen time patients mild first large a therapeutic antipruritic for often course was with full For disrupted improvement also effect pruritus.
and significant of that and different from mild distinct and press scientific with type of sets cause. medical the the of dermatitis of a an represent EPIONE significant study lesers AD guidelines release atopic lists feature figure with scratching factors shown to sleep the of pruritus literature associated is and causative disruption in Results essential the mild appear pruritus need. types a The is atopic severe unmet with Academy suggest through Dermatology, dermatitis. along is to American be two of continued the AD endotypes the The worsening
that recommend antipruritic Currently, only immunomodulatory regiments mild the a dermatology rapid to the produce effect for adequately not topical medications of found treatment and Academy control results after guidelines are tradipitant large The study of filed suggest and indicate therapy in can AD. American and systemic with EPIONE in dermatitis be patients patients. treatment will study. and of need place The a the atopic a could well-tolerated, EPIONE results of significant to tradipitant antipruritic confirmed primary rapid value onset take followup agent of to If algorithm add study like action the in disease. the
results II EPIONE of conducting design Vanda as the determine is EPIONE continue the next study reassess this we and we steps. analyze to currently and plan to of
both to to with remind in randomized we I Briefly, of study To the over our the turn Phase for pipeline in last as Phase other tradipitant III patients gastroparesis. to study study continues touch gastroparesis, our year, study Phase patients upon products that with On before to well diabetic sickness and indication, that’s motion and from idiopathic following a large our now suffered motion the the recruit call of program sickness. completion who began of I enroll II tradipitant you III Kevin. would like have
and a the new to We in drug of motion with by FDA file the expect complete year. program this sickness application hopefully end
indications. aggressively On accepted to the with other an for the syndrome with in In be has Smith-Magenis application also exciting XXXX. for liquid the we by New Year, HETLIOZ, forward formulation drive Vanda FDA to the review continue along submitted
lag to preclude approval with we evidence treatment core HETLIOZ the they to we and remain of and our disorder, in they NDA confident the demonstrate continue For for in features engagement that substantial the approval of significant supplemental jet lag effects required jet for FDA that our meaningful indication. that issues clinically disorder that demonstrates resolve jet of disorder lag
Briefly expect as DSPD of as formulation ongoing and study IIII An in bipolar ongoing. disorder, on psychotic of touch initiate schizophrenia, long-acting a is Fanapt Phase pharmacokinetic in we intervention III disorder DSPD upon is initiated a has sleep well been and injectable phase delayed to observational phase study study atypical study XXXX. in and the Fanapt, to
and updates stop welcome with Kevin. the these Kevin. I’ll And call over turn here to
